Efficacy and toxicity of the antimicrobial peptide M33 produced with different counter-ions

Alessandro Pini, Luisa Lozzi, Andrea Bernini, Jlenia Brunetti, Chiara Falciani, Silvia Scali, Stefano Bindi, Tiziana Di Maggio, Gian Maria Rossolini, Neri Niccolai, Luisa Bracci

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The tetra-branched peptide M33 (Pini et al. in FASEB J 24:1015-1022, 2010) is under evaluation in animal models for its activity as antimicrobial agent in lung infections and sepsis. The preclinical development of a new drug requires medium-scale manufacture for tests of efficacy, biodistribution, pharmacokinetics and toxicity. In order to produce the most suitable peptide form for these purposes, we evaluated the behaviour of the peptide M33 obtained with different counter-ions. We compared activity and toxicity in vitro and in vivo of the peptide M33 produced as trifluoroacetate salt (TFacetate) and as acetate salt. The two forms did not differ substantially in terms of efficacy in vitro or in vivo but showed different toxicities for human cells and in animals. M33-TFacetate proved to be 5-30% more toxic than M33-acetate for cells derived from normal bronchi and cells carrying ΔF508 mutation in the CFTR gene, the most frequent variant in cystic fibrosis. M33-TFacetate produced manifest signs of in vivo toxicity immediately after administration, whereas M33-acetate only generated mild signs, which disappeared within a few hours. The peptide M33-acetate proved more suitable for the development of a new drug, and was therefore chosen for further characterization.

Original languageEnglish
Pages (from-to)467-473
Number of pages7
JournalAmino Acids
Volume43
Issue number1
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Radiation counters
Toxicity
Trifluoroacetic Acid
Ions
Acetates
Peptides
Salts
Animals
Pharmacokinetics
Poisons
Bronchi
Anti-Infective Agents
Cystic Fibrosis
Pharmaceutical Preparations
Sepsis
Animal Models
Genes
Cells
Lung
Mutation

Keywords

  • Antimicrobial peptides
  • Branched peptides
  • Cystic fibrosis
  • Gram-negative bacteria
  • Peptide toxicity
  • Trifluoroacetic acid

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Pini, A., Lozzi, L., Bernini, A., Brunetti, J., Falciani, C., Scali, S., ... Bracci, L. (2012). Efficacy and toxicity of the antimicrobial peptide M33 produced with different counter-ions. Amino Acids, 43(1), 467-473. https://doi.org/10.1007/s00726-011-1103-z

Efficacy and toxicity of the antimicrobial peptide M33 produced with different counter-ions. / Pini, Alessandro; Lozzi, Luisa; Bernini, Andrea; Brunetti, Jlenia; Falciani, Chiara; Scali, Silvia; Bindi, Stefano; Di Maggio, Tiziana; Rossolini, Gian Maria; Niccolai, Neri; Bracci, Luisa.

In: Amino Acids, Vol. 43, No. 1, 07.2012, p. 467-473.

Research output: Contribution to journalArticle

Pini, A, Lozzi, L, Bernini, A, Brunetti, J, Falciani, C, Scali, S, Bindi, S, Di Maggio, T, Rossolini, GM, Niccolai, N & Bracci, L 2012, 'Efficacy and toxicity of the antimicrobial peptide M33 produced with different counter-ions', Amino Acids, vol. 43, no. 1, pp. 467-473. https://doi.org/10.1007/s00726-011-1103-z
Pini, Alessandro ; Lozzi, Luisa ; Bernini, Andrea ; Brunetti, Jlenia ; Falciani, Chiara ; Scali, Silvia ; Bindi, Stefano ; Di Maggio, Tiziana ; Rossolini, Gian Maria ; Niccolai, Neri ; Bracci, Luisa. / Efficacy and toxicity of the antimicrobial peptide M33 produced with different counter-ions. In: Amino Acids. 2012 ; Vol. 43, No. 1. pp. 467-473.
@article{007c12ee32484f2fb3d4ee30d7a76cf1,
title = "Efficacy and toxicity of the antimicrobial peptide M33 produced with different counter-ions",
abstract = "The tetra-branched peptide M33 (Pini et al. in FASEB J 24:1015-1022, 2010) is under evaluation in animal models for its activity as antimicrobial agent in lung infections and sepsis. The preclinical development of a new drug requires medium-scale manufacture for tests of efficacy, biodistribution, pharmacokinetics and toxicity. In order to produce the most suitable peptide form for these purposes, we evaluated the behaviour of the peptide M33 obtained with different counter-ions. We compared activity and toxicity in vitro and in vivo of the peptide M33 produced as trifluoroacetate salt (TFacetate) and as acetate salt. The two forms did not differ substantially in terms of efficacy in vitro or in vivo but showed different toxicities for human cells and in animals. M33-TFacetate proved to be 5-30{\%} more toxic than M33-acetate for cells derived from normal bronchi and cells carrying ΔF508 mutation in the CFTR gene, the most frequent variant in cystic fibrosis. M33-TFacetate produced manifest signs of in vivo toxicity immediately after administration, whereas M33-acetate only generated mild signs, which disappeared within a few hours. The peptide M33-acetate proved more suitable for the development of a new drug, and was therefore chosen for further characterization.",
keywords = "Antimicrobial peptides, Branched peptides, Cystic fibrosis, Gram-negative bacteria, Peptide toxicity, Trifluoroacetic acid",
author = "Alessandro Pini and Luisa Lozzi and Andrea Bernini and Jlenia Brunetti and Chiara Falciani and Silvia Scali and Stefano Bindi and {Di Maggio}, Tiziana and Rossolini, {Gian Maria} and Neri Niccolai and Luisa Bracci",
year = "2012",
month = "7",
doi = "10.1007/s00726-011-1103-z",
language = "English",
volume = "43",
pages = "467--473",
journal = "Amino Acids",
issn = "0939-4451",
publisher = "Springer Wien",
number = "1",

}

TY - JOUR

T1 - Efficacy and toxicity of the antimicrobial peptide M33 produced with different counter-ions

AU - Pini, Alessandro

AU - Lozzi, Luisa

AU - Bernini, Andrea

AU - Brunetti, Jlenia

AU - Falciani, Chiara

AU - Scali, Silvia

AU - Bindi, Stefano

AU - Di Maggio, Tiziana

AU - Rossolini, Gian Maria

AU - Niccolai, Neri

AU - Bracci, Luisa

PY - 2012/7

Y1 - 2012/7

N2 - The tetra-branched peptide M33 (Pini et al. in FASEB J 24:1015-1022, 2010) is under evaluation in animal models for its activity as antimicrobial agent in lung infections and sepsis. The preclinical development of a new drug requires medium-scale manufacture for tests of efficacy, biodistribution, pharmacokinetics and toxicity. In order to produce the most suitable peptide form for these purposes, we evaluated the behaviour of the peptide M33 obtained with different counter-ions. We compared activity and toxicity in vitro and in vivo of the peptide M33 produced as trifluoroacetate salt (TFacetate) and as acetate salt. The two forms did not differ substantially in terms of efficacy in vitro or in vivo but showed different toxicities for human cells and in animals. M33-TFacetate proved to be 5-30% more toxic than M33-acetate for cells derived from normal bronchi and cells carrying ΔF508 mutation in the CFTR gene, the most frequent variant in cystic fibrosis. M33-TFacetate produced manifest signs of in vivo toxicity immediately after administration, whereas M33-acetate only generated mild signs, which disappeared within a few hours. The peptide M33-acetate proved more suitable for the development of a new drug, and was therefore chosen for further characterization.

AB - The tetra-branched peptide M33 (Pini et al. in FASEB J 24:1015-1022, 2010) is under evaluation in animal models for its activity as antimicrobial agent in lung infections and sepsis. The preclinical development of a new drug requires medium-scale manufacture for tests of efficacy, biodistribution, pharmacokinetics and toxicity. In order to produce the most suitable peptide form for these purposes, we evaluated the behaviour of the peptide M33 obtained with different counter-ions. We compared activity and toxicity in vitro and in vivo of the peptide M33 produced as trifluoroacetate salt (TFacetate) and as acetate salt. The two forms did not differ substantially in terms of efficacy in vitro or in vivo but showed different toxicities for human cells and in animals. M33-TFacetate proved to be 5-30% more toxic than M33-acetate for cells derived from normal bronchi and cells carrying ΔF508 mutation in the CFTR gene, the most frequent variant in cystic fibrosis. M33-TFacetate produced manifest signs of in vivo toxicity immediately after administration, whereas M33-acetate only generated mild signs, which disappeared within a few hours. The peptide M33-acetate proved more suitable for the development of a new drug, and was therefore chosen for further characterization.

KW - Antimicrobial peptides

KW - Branched peptides

KW - Cystic fibrosis

KW - Gram-negative bacteria

KW - Peptide toxicity

KW - Trifluoroacetic acid

UR - http://www.scopus.com/inward/record.url?scp=84862762312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862762312&partnerID=8YFLogxK

U2 - 10.1007/s00726-011-1103-z

DO - 10.1007/s00726-011-1103-z

M3 - Article

C2 - 21984381

AN - SCOPUS:84862762312

VL - 43

SP - 467

EP - 473

JO - Amino Acids

JF - Amino Acids

SN - 0939-4451

IS - 1

ER -